PPA
ENTA icon

Parametric Portfolio Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Parametric Portfolio Associates’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$5.69M Sell
79,959
-10,303
-11% -$670K ﹤0.01% 1760
2021
Q4 		$6.75M Buy
90,262
+11,837
+15% +$929K ﹤0.01% 1658
2021
Q3 		$4.46M Buy
78,425
+16,639
+27% +$823K ﹤0.01% 1912
2021
Q2 		$2.72M Sell
61,786
-44,756
-42% -$2.19M ﹤0.01% 2259
2021
Q1 		$5.25M Buy
106,542
+55,936
+111% +$2.79M ﹤0.01% 2130
2020
Q4 		$2.13M Buy
50,606
+2,780
+6% +$122K ﹤0.01% 2611
2020
Q3 		$2.19M Buy
47,826
+12,055
+34% +$584K ﹤0.01% 2461
2020
Q2 		$1.8M Sell
35,771
-394
-1% -$20.4K ﹤0.01% 2561
2020
Q1 		$1.86M Buy
36,165
+9,657
+36% +$515K ﹤0.01% 2426
2019
Q4 		$1.64M Sell
26,508
-3,543
-12% -$220K ﹤0.01% 2816
2019
Q3 		$1.8M Buy
30,051
+508
+2% +$37.7K ﹤0.01% 2694
2019
Q2 		$2.49M Sell
29,543
-2,489
-8% -$224K ﹤0.01% 2520
2019
Q1 		$3.06M Sell
32,032
-3,165
-9% -$284K ﹤0.01% 2359
2018
Q4 		$2.49M Buy
35,197
+5,860
+20% +$449K ﹤0.01% 2432
2018
Q3 		$2.51M Sell
29,337
-12,009
-29% -$1.2M ﹤0.01% 2553
2018
Q2 		$4.79M Buy
41,346
+9,388
+29% +$937K ﹤0.01% 2000
2018
Q1 		$2.59M Buy
31,958
+8,172
+34% +$629K ﹤0.01% 2436
2017
Q4 		$1.4M Buy
23,786
+7,163
+43% +$359K ﹤0.01% 2840
2017
Q3 		$778K Buy
16,623
+3,847
+30% +$155K ﹤0.01% 3174
2017
Q2 		$460K Buy
12,776
+922
+8% +$29.5K ﹤0.01% 3410
2017
Q1 		$365K Buy
11,854
+1,989
+20% +$61.9K ﹤0.01% 3355
2016
Q4 		$330K Sell
9,865
-1,764
-15% -$50.6K ﹤0.01% 3377
2016
Q3 		$309K Sell
11,629
-4,545
-28% -$106K ﹤0.01% 3406
2016
Q2 		$357K Sell
16,174
-6,705
-29% -$176K ﹤0.01% 3373
2016
Q1 		$672K Buy
22,879
+5,631
+33% +$157K ﹤0.01% 3172
2015
Q4 		$570K Buy
17,248
+331
+2% +$10.8K ﹤0.01% 3160
2015
Q3 		$611K Sell
16,917
-2,287
-12% -$98.2K ﹤0.01% 2617
2015
Q2 		$864K Buy
19,204
+6,076
+46% +$236K ﹤0.01% 2907
2015
Q1 		$402K Sell
13,128
-1,508
-10% -$58.7K ﹤0.01% 3400
2014
Q4 		$744K Sell
14,636
-31,177
-68% -$1.4M ﹤0.01% 3006
2014
Q3 		$1.81M Buy
45,813
+39,351
+609% +$1.57M ﹤0.01% 2173
2014
Q2 		$278K Buy
+6,462
New +$247K ﹤0.01% 3559

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parametric Portfolio Associates's ENTA Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Enanta Pharmaceuticals (ENTA) stake by 11% in Q1 2022, selling an estimated $670K and leaving 79,959 shares worth $5.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1760.

Parametric Portfolio Associates first reported a position in ENTA in Q2 2014 and has held it in 32 quarters since. The position peaked at $6.75M in Q4 2021. 169 funds tracked by Wall St. Rank hold ENTA as of Q1 2022.

  • Parametric Portfolio Associates held 79,959 shares of Enanta Pharmaceuticals worth $5.69M as of Q1 2022.
  • Parametric Portfolio Associates sold 10,303 Enanta Pharmaceuticals shares in Q1 2022, an estimated $670K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1760 holding.
  • Parametric Portfolio Associates first reported a position in Enanta Pharmaceuticals in Q2 2014 and has held it in 32 quarters since.
  • Parametric Portfolio Associates's Enanta Pharmaceuticals position peaked at $6.75M in Q4 2021.
  • 169 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.